Independent show-cause notices remain separate proceedings, while customs adjudication challenges should ordinarily follow the statutory appellate rem...
Institutional incapacity in customs settlement proceedings excludes non-functional quorum periods from statutory disposal timelines, preventing automa...
Interactive touchscreen panels with integrated computing functions fall under automatic data-processing machines rather than display monitors for cust...
Ex parte injunction service requirements were substantially met, while civil recovery and SFIO investigation into provident fund defalcation continued...
Enforcement of resolution-plan directions continues without a Supreme Court stay, preventing suspension of redistribution and escrowed-fund distributi...
Third-party ownership claims over attached property require Special Court adjudication where purchasers lack registered sale deeds and bona fides rema...
Pure-agent reimbursements in clearing and forwarding services are excluded from taxable value when qualifying third-party payments are properly record...
The CESTAT held that insulin products manufactured using recombinant DNA technology would qualify as 'mono-component insulin' and are entitled to exemption under Notification No. 12/2012 Customs dated March 17, 2012, as they are lifesaving drugs. The classification of the imported insulin products is based on their content rather than source. The Tribunal accepted that 'mono-component' refers to the purity of insulin rather than its source, and there was no evidence that the disputed products had impurity levels higher than 1 PPM. The CESTAT upheld the classification of the imported insulin products under chapter heading 3004 31 10, making them eligible for the exemption as lifesaving drugs.
The CESTAT held that insulin products manufactured using recombinant DNA technology would qualify as 'mono-component insulin' and are entitled to exemption under Notification No. 12/2012 Customs dated March 17, 2012, as they are lifesaving drugs. The classification of the imported insulin products is based on their content rather than source. The Tribunal accepted that 'mono-component' refers to the purity of insulin rather than its source, and there was no evidence that the disputed products had impurity levels higher than 1 PPM. The CESTAT upheld the classification of the imported insulin products under chapter heading 3004 31 10, making them eligible for the exemption as lifesaving drugs.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
of 4782
Join Channel
TaxTMI 
